908 Devices Inc. (NASDAQ: MASS) Stock Competitors & Peer Comparison

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, ALC has a market cap of 35.6B. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while ALC trades at $74.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas ALC's P/E ratio is 23.31. In terms of profitability, MASS's ROE is -0.17%, compared to ALC's ROE of +0.03%. Regarding short-term risk, MASS is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for MASS.Check ALC's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, STE has a market cap of 25.7B. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while STE trades at $264.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas STE's P/E ratio is 25.37. In terms of profitability, MASS's ROE is -0.17%, compared to STE's ROE of +0.11%. Regarding short-term risk, MASS is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for MASS.Check STE's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, MLAB has a market cap of 781.3M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while MLAB trades at $139.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas MLAB's P/E ratio is 14.03. In terms of profitability, MASS's ROE is -0.17%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, MASS is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for MASS.Check MLAB's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, QDEL has a market cap of 736.9M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while QDEL trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas QDEL's P/E ratio is 8.01. In terms of profitability, MASS's ROE is -0.17%, compared to QDEL's ROE of -0.20%. Regarding short-term risk, MASS is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for MASS.Check QDEL's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, MOBI has a market cap of 438.4M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while MOBI trades at $13.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas MOBI's P/E ratio is -4.45. In terms of profitability, MASS's ROE is -0.17%, compared to MOBI's ROE of -23.36%. Regarding short-term risk, MASS is more volatile compared to MOBI. This indicates higher risk in terms of short-term price fluctuations for MASS.Check MOBI's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, SI has a market cap of 432.9M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while SI trades at $20.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas SI's P/E ratio is -11.96. In terms of profitability, MASS's ROE is -0.17%, compared to SI's ROE of -0.26%. Regarding short-term risk, MASS is more volatile compared to SI. This indicates higher risk in terms of short-term price fluctuations for MASS.Check SI's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, BWAY has a market cap of 396.5M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while BWAY trades at $10.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas BWAY's P/E ratio is 25.68. In terms of profitability, MASS's ROE is -0.17%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, MASS is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for MASS.Check BWAY's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, LAB has a market cap of 279.3M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while LAB trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas LAB's P/E ratio is -10.11. In terms of profitability, MASS's ROE is -0.17%, compared to LAB's ROE of -0.08%. Regarding short-term risk, MASS is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for MASS.Check LAB's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, ANIK has a market cap of 179.5M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while ANIK trades at $13.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas ANIK's P/E ratio is 27.35. In terms of profitability, MASS's ROE is -0.17%, compared to ANIK's ROE of -0.01%. Regarding short-term risk, MASS is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for MASS.Check ANIK's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas EDAP's P/E ratio is -5.80. In terms of profitability, MASS's ROE is -0.17%, compared to EDAP's ROE of -2.41%. Regarding short-term risk, MASS is more volatile compared to EDAP. This indicates higher risk in terms of short-term price fluctuations for MASS.Check EDAP's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, TRIB has a market cap of 124.7M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while TRIB trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas TRIB's P/E ratio is -0.10. In terms of profitability, MASS's ROE is -0.17%, compared to TRIB's ROE of +0.49%. Regarding short-term risk, MASS is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for MASS.Check TRIB's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, APYX has a market cap of 118.4M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while APYX trades at $2.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas APYX's P/E ratio is -14.05. In terms of profitability, MASS's ROE is -0.17%, compared to APYX's ROE of -0.71%. Regarding short-term risk, MASS is less volatile compared to APYX. This indicates lower risk in terms of short-term price fluctuations for MASS.Check APYX's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, SKIN has a market cap of 106.3M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while SKIN trades at $16.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas SKIN's P/E ratio is -74.14. In terms of profitability, MASS's ROE is -0.17%, compared to SKIN's ROE of -0.32%. Regarding short-term risk, MASS is less volatile compared to SKIN. This indicates lower risk in terms of short-term price fluctuations for MASS.Check SKIN's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, NYXH has a market cap of 91.6M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while NYXH trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas NYXH's P/E ratio is -0.36. In terms of profitability, MASS's ROE is -0.17%, compared to NYXH's ROE of -1.57%. Regarding short-term risk, MASS is more volatile compared to NYXH. This indicates higher risk in terms of short-term price fluctuations for MASS.Check NYXH's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, MDAI has a market cap of 41.8M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while MDAI trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas MDAI's P/E ratio is -2.89. In terms of profitability, MASS's ROE is -0.17%, compared to MDAI's ROE of +1.01%. Regarding short-term risk, MASS is less volatile compared to MDAI. This indicates lower risk in terms of short-term price fluctuations for MASS.Check MDAI's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, BEAT has a market cap of 22.3M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while BEAT trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas BEAT's P/E ratio is -0.78. In terms of profitability, MASS's ROE is -0.17%, compared to BEAT's ROE of -4.03%. Regarding short-term risk, MASS is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for MASS.Check BEAT's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, ITOC has a market cap of 13.5M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while ITOC trades at $1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas ITOC's P/E ratio is -0.47. In terms of profitability, MASS's ROE is -0.17%, compared to ITOC's ROE of -0.60%. Regarding short-term risk, MASS is less volatile compared to ITOC. This indicates lower risk in terms of short-term price fluctuations for MASS.Check ITOC's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, DRIO has a market cap of 12.3M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while DRIO trades at $1.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas DRIO's P/E ratio is -0.22. In terms of profitability, MASS's ROE is -0.17%, compared to DRIO's ROE of +0.95%. Regarding short-term risk, MASS is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for MASS.Check DRIO's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, MDAIW has a market cap of 12.2M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while MDAIW trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas MDAIW's P/E ratio is -1.08. In terms of profitability, MASS's ROE is -0.17%, compared to MDAIW's ROE of +1.01%. Regarding short-term risk, MASS is less volatile compared to MDAIW. This indicates lower risk in terms of short-term price fluctuations for MASS.Check MDAIW's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, BEATW has a market cap of 6.6M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while BEATW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas BEATW's P/E ratio is -0.02. In terms of profitability, MASS's ROE is -0.17%, compared to BEATW's ROE of -4.03%. Regarding short-term risk, MASS is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for MASS.Check BEATW's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while QTEXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, MASS's ROE is -0.17%, compared to QTEXW's ROE of N/A. Regarding short-term risk, MASS is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for MASS.Check QTEXW's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, WOK has a market cap of 2.9M. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while WOK trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas WOK's P/E ratio is N/A. In terms of profitability, MASS's ROE is -0.17%, compared to WOK's ROE of -0.19%. Regarding short-term risk, MASS is less volatile compared to WOK. This indicates lower risk in terms of short-term price fluctuations for MASS.Check WOK's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, FEED has a market cap of 951.4K. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while FEED trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas FEED's P/E ratio is -0.15. In terms of profitability, MASS's ROE is -0.17%, compared to FEED's ROE of -0.60%. Regarding short-term risk, MASS is less volatile compared to FEED. This indicates lower risk in terms of short-term price fluctuations for MASS.Check FEED's competition here

908 Devices Inc. (NASDAQ: MASS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MASS stands at 405M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, MASS is priced at $9.74 on the NASDAQ, while TIVC trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MASS currently has a P/E ratio of -16.23, whereas TIVC's P/E ratio is -0.04. In terms of profitability, MASS's ROE is -0.17%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, MASS is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for MASS.Check TIVC's competition here